An analysis of the impact on total cost of care within a pharmacist-led comprehensive medication management program

IF 1.3 Q4 PHARMACOLOGY & PHARMACY
Julie Anne Earby Pharm.D., Tiffany Nicole Jenkins Pharm.D., Abigail Marie Johnson Pharm.D., Victoria Dianne Marchwinski Pharm.D., Devin Marie Schmidt Pharm.D.
{"title":"An analysis of the impact on total cost of care within a pharmacist-led comprehensive medication management program","authors":"Julie Anne Earby Pharm.D.,&nbsp;Tiffany Nicole Jenkins Pharm.D.,&nbsp;Abigail Marie Johnson Pharm.D.,&nbsp;Victoria Dianne Marchwinski Pharm.D.,&nbsp;Devin Marie Schmidt Pharm.D.","doi":"10.1002/jac5.2007","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The rise in health care expenditures continues to pose a significant concern regarding the longevity of the current health care system design. The literature has demonstrated a positive return on investment (ROI) when pharmacists perform medication management services. Building upon positive ROI literature, a clinically integrated network (CIN) in Michigan developed an approach to patient targeting for comprehensive medication management (CMM) services in existing alternative payment model (APM) Medicare Advantage, Medicaid, and Commercial contracts.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>The primary objective of this study was to examine the real-world impact of an advanced ambulatory care pharmacy model, inclusive of embedded clinic-based ambulatory pharmacists, centralized ambulatory pharmacists, centralized population health pharmacists, and specially trained pharmacy technicians, on the total cost of care (TCOC) within a large integrated health system.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>For CMM dates of service occurring in calendar year 2022, pharmacy and medical claims were evaluated during the 6-month period prior to and following the initial CMM patient encounter. Upon completion of the study period, data were evaluated to assess TCOC and utilization trends for the study population.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Statistically significant differences in median TCOC ($1427.84, <i>p</i> &lt; 0.001), prescription drug costs ($222.82, <i>p</i> &lt; 0.001), and medical costs ($462.26, <i>p</i> &lt; 0.001) were observed between the pre-CMM and post-CMM timeframes for the study population. A 16% reduction in hospital admissions was observed between the pre-CMM and post-CMM timeframes.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>This study further supports that pharmacist intervention as part of a CMM program can favorably affect health care costs. Criteria such as a population's benchmark costs and utilization, insurance product types, and core conditions present can help determine whether expanding or initiating CMM services could be beneficial in improving care and health care costs.</p>\n </section>\n </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2007","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jac5.2007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The rise in health care expenditures continues to pose a significant concern regarding the longevity of the current health care system design. The literature has demonstrated a positive return on investment (ROI) when pharmacists perform medication management services. Building upon positive ROI literature, a clinically integrated network (CIN) in Michigan developed an approach to patient targeting for comprehensive medication management (CMM) services in existing alternative payment model (APM) Medicare Advantage, Medicaid, and Commercial contracts.

Objectives

The primary objective of this study was to examine the real-world impact of an advanced ambulatory care pharmacy model, inclusive of embedded clinic-based ambulatory pharmacists, centralized ambulatory pharmacists, centralized population health pharmacists, and specially trained pharmacy technicians, on the total cost of care (TCOC) within a large integrated health system.

Methods

For CMM dates of service occurring in calendar year 2022, pharmacy and medical claims were evaluated during the 6-month period prior to and following the initial CMM patient encounter. Upon completion of the study period, data were evaluated to assess TCOC and utilization trends for the study population.

Results

Statistically significant differences in median TCOC ($1427.84, p < 0.001), prescription drug costs ($222.82, p < 0.001), and medical costs ($462.26, p < 0.001) were observed between the pre-CMM and post-CMM timeframes for the study population. A 16% reduction in hospital admissions was observed between the pre-CMM and post-CMM timeframes.

Discussion

This study further supports that pharmacist intervention as part of a CMM program can favorably affect health care costs. Criteria such as a population's benchmark costs and utilization, insurance product types, and core conditions present can help determine whether expanding or initiating CMM services could be beneficial in improving care and health care costs.

Abstract Image

分析药剂师主导的综合药物管理计划对总护理成本的影响
导言:医疗保健支出的增加继续对当前医疗保健系统设计的寿命构成严重威胁。有文献表明,药剂师提供药物管理服务具有积极的投资回报(ROI)。在积极投资回报率文献的基础上,密歇根州的一家临床综合网络(CIN)开发了一种方法,在现有的替代支付模式(APM)医疗保险优势项目、医疗补助项目和商业合同中为患者提供综合药物管理(CMM)服务。 研究目的 本研究的主要目的是在一个大型综合医疗系统内,考察先进的非住院医疗药房模式(包括嵌入式诊所非住院药剂师、集中式非住院药剂师、集中式人口健康药剂师和经过专门培训的药剂技师)对总医疗成本(TCOC)的实际影响。 方法 对 2022 日历年发生的 CMM 服务日期、首次 CMM 患者就诊前后 6 个月内的药房和医疗报销进行评估。研究期结束后,对数据进行评估,以评估研究人群的 TCOC 和使用趋势。 结果 在研究人群中,CMM 前和 CMM 后的中位 TCOC(1427.84 美元,p <0.001)、处方药费用(222.82 美元,p <0.001)和医疗费用(462.26 美元,p <0.001)均有明显的统计学差异。在 CMM 实施前和实施后的时间段内,住院人数减少了 16%。 讨论 本研究进一步证明,药剂师干预作为 CMM 计划的一部分,可以对医疗成本产生有利影响。人口的基准成本和使用率、保险产品类型和存在的核心病症等标准有助于确定扩大或启动 CMM 服务是否有利于改善护理和医疗成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信